Clinical Variables Influencing Outcomes in Patients with Atypical Intradermal Smooth Muscle Neoplasms (Formerly Cutaneous Leiomyosarcomas): Single-Institution Study of 95 Surgical Patients.
Atypical intradermal smooth muscle neoplasm
Cutaneous leiomyosarcoma
Dermal neoplasm
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
16 Aug 2024
16 Aug 2024
Historique:
received:
05
02
2024
accepted:
13
05
2024
medline:
16
8
2024
pubmed:
16
8
2024
entrez:
16
8
2024
Statut:
aheadofprint
Résumé
Atypical intradermal smooth muscle neoplasm, also commonly termed cutaneous leiomyosarcoma, is a soft tissue tumor with a low risk of aggressive behavior. These lesions arise in the dermis with possible superficial subcutaneous extension, demonstrate cytologic atypia, and often show mitotic activity. A retrospective review of patient demographics, tumor characteristics, and treatment methods was conducted in a consecutive series of patients presenting to MD Anderson Cancer Center (MDACC) from 2002 to 2021 (n = 95). All pathology was reviewed by MDACC pathologists and determined to be atypical intradermal smooth muscle neoplasm. Median age at diagnosis was 58 years (range 22-86), and 74% were male. Ninety-five percent (n = 90) of patients identified as White, non-Hispanic. Most tumors were slow-growing, solitary, and painless nodules. Tumors were in the lower extremities (44.2%), followed by the upper extremity (28.4%), trunk (22.1%), and head and neck (5.2%). All patients (n = 44, 46.3%) who had a punch/incisional biopsy for diagnostic purposes had a subsequent tumor excision. Unplanned excision or excisional biopsy was performed on the remaining 46 (48%) patients. Of this subset, 41 of the 46 aforementioned patients (89%) had positive margins and underwent re-excision. Final pathology in 25/38 (66%) re-excision specimens was negative for residual tumor despite an initial positive margin. Two patients in the cohort had local recurrence 2 and 3 years after initial surgery. Both patients had positive margins, underwent excision of the recurrent tumor, and remain free of disease. After median follow-up of 6.9 years (range 1 day-18 years), 5-year recurrence-free survival was 96% and overall survival (OS) of the entire cohort was 78%. In this study of consecutive patients presenting with atypical intradermal smooth muscle neoplasm, we found good OS and local control after definitive surgical excision with negative margins, including excisional biopsy with close margins. Atypical intradermal smooth muscle neoplasm is unlikely to metastasize and has an excellent prognosis. Guidelines to determine optimal surveillance strategies for these patients should be revisited.
Sections du résumé
BACKGROUND
BACKGROUND
Atypical intradermal smooth muscle neoplasm, also commonly termed cutaneous leiomyosarcoma, is a soft tissue tumor with a low risk of aggressive behavior. These lesions arise in the dermis with possible superficial subcutaneous extension, demonstrate cytologic atypia, and often show mitotic activity.
METHODS
METHODS
A retrospective review of patient demographics, tumor characteristics, and treatment methods was conducted in a consecutive series of patients presenting to MD Anderson Cancer Center (MDACC) from 2002 to 2021 (n = 95). All pathology was reviewed by MDACC pathologists and determined to be atypical intradermal smooth muscle neoplasm.
RESULTS
RESULTS
Median age at diagnosis was 58 years (range 22-86), and 74% were male. Ninety-five percent (n = 90) of patients identified as White, non-Hispanic. Most tumors were slow-growing, solitary, and painless nodules. Tumors were in the lower extremities (44.2%), followed by the upper extremity (28.4%), trunk (22.1%), and head and neck (5.2%). All patients (n = 44, 46.3%) who had a punch/incisional biopsy for diagnostic purposes had a subsequent tumor excision. Unplanned excision or excisional biopsy was performed on the remaining 46 (48%) patients. Of this subset, 41 of the 46 aforementioned patients (89%) had positive margins and underwent re-excision. Final pathology in 25/38 (66%) re-excision specimens was negative for residual tumor despite an initial positive margin. Two patients in the cohort had local recurrence 2 and 3 years after initial surgery. Both patients had positive margins, underwent excision of the recurrent tumor, and remain free of disease. After median follow-up of 6.9 years (range 1 day-18 years), 5-year recurrence-free survival was 96% and overall survival (OS) of the entire cohort was 78%.
CONCLUSION
CONCLUSIONS
In this study of consecutive patients presenting with atypical intradermal smooth muscle neoplasm, we found good OS and local control after definitive surgical excision with negative margins, including excisional biopsy with close margins. Atypical intradermal smooth muscle neoplasm is unlikely to metastasize and has an excellent prognosis. Guidelines to determine optimal surveillance strategies for these patients should be revisited.
Identifiants
pubmed: 39150618
doi: 10.1245/s10434-024-15528-x
pii: 10.1245/s10434-024-15528-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.
Références
Kraft S. CDM fletcher. Atypical intradermal smooth muscle neoplasms: clinicopathologic analysis of 84 cases and a reappraisal of cutaneous “Leiomyosarcoma.” Am J Surg Pathol. 2011;35(4):599–607.
doi: 10.1097/PAS.0b013e31820e6093
pubmed: 21358302
Sandhu N, et al. Cutaneous leiomyosarcoma: a SEER database analysis. Dermatol Surg. 2020;46(2):159–64.
doi: 10.1097/DSS.0000000000002029
pubmed: 31306276
Massi D, et al. Primary cutaneous leiomyosarcoma: clinicopathological analysis of 36 cases. Histopathology. 2010;56(2):251–62.
doi: 10.1111/j.1365-2559.2009.03471.x
pubmed: 20102404
Hall BJ, et al. Atypical intradermal smooth muscle neoplasms (formerly cutaneous leiomyosarcomas): case series, immunohistochemical profile and review of the literature. Appl Immunohistochem Mol Morphol. 2013;21(2):132–8.
doi: 10.1097/PAI.0b013e31825f4af2
pubmed: 22820664
Wollina U, et al. A 10-year analysis of cutaneous mesenchymal tumors (sarcomas and related entities) in a skin cancer center. Int J Dermatol. 2013;52(10):1189–97.
doi: 10.1111/j.1365-4632.2012.05484.x
pubmed: 23829640
Zacher M, et al. Primary leiomyosarcoma of the skin: a comprehensive review on diagnosis and treatment. Med Oncol. 2018;35(10):135.
doi: 10.1007/s12032-018-1196-2
pubmed: 30140957
Kazlouskaya V, Lai YC, Khachemoune A. Leiomyosarcoma of the skin: review of the literature with an emphasis on prognosis and management. Int J Dermatol. 2020;59(2):165–72.
doi: 10.1111/ijd.14705
pubmed: 31729020
Planet C, et al. Clinicopathologic and molecular analyses of cutaneous leiomyosarcoma: A retrospective, multicenter study of 79 cases. J Am Acad Dermatol. 2023;88(1):215–6.
doi: 10.1016/j.jaad.2022.03.066
pubmed: 35489551
Vargas-Mora P, et al. Primary cutaneous leiomyosarcoma: a single institution study treated with modified Mohs surgery. Int J Dermatol. 2023;62(1):e10–3.
doi: 10.1111/ijd.16412
pubmed: 36039993
Wang WL, et al. Sarcoma metastases to the skin: a clinicopathologic study of 65 patients. Cancer. 2012;118(11):2900–4.
doi: 10.1002/cncr.26590
pubmed: 21989966
Oliver G, et al. Cutaneous and subcutaneous leiomyosarcoma: a clinicopathological review of 14 cases with reference to antidesmin staining and nuclear DNA patterns studied by flow cytometry. Br J Dermatol. 1991;124(3):252–7.
doi: 10.1111/j.1365-2133.1991.tb00569.x
pubmed: 2018731
Aneiros-Fernandez J, et al. Primary cutaneous and subcutaneous leiomyosarcomas: evolution and prognostic factors. Eur J Dermatol. 2016;26(1):9–12.
doi: 10.1684/ejd.2015.2681
pubmed: 26678649
Wong GN, et al. Cutaneous leiomyosarcoma: dermal and subcutaneous. Austral J Dermatol. 2020;61(3):243–9.
doi: 10.1111/ajd.13307
Ho J, Collie CJ, What's new in dermatopathology 2023: WHO 5th edition updates. J Pathol Transl Med. 2023;57(6):337-340.
De Giorgi V, et al. Superficial cutaneous leiomyosarcoma: a rare, misleading tumor. Am J Clin Dermatol. 2008;9:185–7.
doi: 10.2165/00128071-200809030-00008
pubmed: 18429649
Fauth CT, et al. Superficial leiomyosarcoma: a clinicopathologic review and update. J Cutaneous Pathol. 2010;37(2):269–76.
doi: 10.1111/j.1600-0560.2009.01405.x
Menko FH, et al. Hereditary leiomyomatosis and renal cell cancer (HLRCC): renal cancer risk, surveillance and treatment. Fam Cancer. 2014;13(4):637–44.
doi: 10.1007/s10689-014-9735-2
pubmed: 25012257
pmcid: 4574691
Fields JP, Helwig EB. Leiomyosarcoma of the skin and subcutaneous tissue. Cancer. 1981;47(1):156–69.
doi: 10.1002/1097-0142(19810101)47:1<156::AID-CNCR2820470127>3.0.CO;2-#
pubmed: 7459804
Auroy S, et al. Primary cutaneous leiomyosarcoma: 32 cases [in French]. Annales de dermatologie et de venereologie. 1999;126(3):235–42.
pubmed: 10394436
Farshid G, et al. Leiomyosarcoma of somatic soft tissues: a tumor of vascular origin with multivariate analysis of outcome in 42 cases. Am J Surg Pathol. 2002;26(1):14–24.
doi: 10.1097/00000478-200201000-00002
pubmed: 11756765
Berzal-Cantalejo F, et al. Desmoplastic cutaneous leiomyosarcoma: Case report and review of the literature. J Cutaneous Pathol. 2006;33:29–31.
doi: 10.1111/j.1600-0560.2006.00542.x
Annest NM, et al. Cutaneous leiomyosarcoma: a tumor of the head and neck. Dermatol Surg. 2007;33(5):628–33.
pubmed: 17451590
Deneve JL, et al. Cutaneous leiomyosarcoma: treatment and outcomes with a standardized margin of resection. Cancer Control. 2013;20(4):307–12.
doi: 10.1177/107327481302000408
pubmed: 24077407
Glazer ES. C Prieto-Granada, JS Zager, Current approaches to cutaneous sarcomas: dermatofibrosarcoma protuberans and cutaneous leiomyosarcoma. Curr Probl Cancer. 2015;39(4):248–57.
doi: 10.1016/j.currproblcancer.2015.07.006
pubmed: 26276213
Humphreys TR, Finkelstein DH, Lee JB. Superficial leiomyosarcoma treated with Mohs micrographic surgery. Dermatol Surg. 2004;30(1):108–12.
pubmed: 14692939
Starling J, Coldiron BM. Mohs micrographic surgery for the treatment of cutaneous leiomyosarcoma. J Am Acad Dermatol. 2011;64(6):1119–22.
doi: 10.1016/j.jaad.2010.11.051
pubmed: 21571171
Svarvar C, et al. Clinical course of nonvisceral soft tissue leiomyosarcoma in 225 patients from the Scandinavian Sarcoma Group. Cancer. 2007;109(2):282–91.
doi: 10.1002/cncr.22395
pubmed: 17154171